[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.202.12. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 1988

Evaluation of the Efficacy of Topical Bufexamac in Epidermolysis Bullosa SimplexA Double-blind Placebo-Controlled Crossover Trial

Author Affiliations

From the Department of Dermatology, The University of Alabama at Birmingham School of Medicine (Drs Fine and Johnson), and the Dermatology Section, Medical Service, Birmingham (Ala) Veterans Administration Medical Center (Dr Fine).

Arch Dermatol. 1988;124(11):1669-1672. doi:10.1001/archderm.1988.01670110029006
Abstract

• Although, as yet, there is no specific treatment of epidermolysis bullosa (EB) simplex, anecdotal reports suggest the possible efficacy of one of the newer topical nonsteroidal anti-inflammatory agents, bufexamac. To determine whether bufexamac has any role in the management of this disease, a double-blind placebo-controlled crossover clinical trial was undertaken with ten patients (nine, Weber-Cockayne variant; one, generalized EB simplex). Each of the two preparations was applied four times daily during the 2 four-week treatment periods. Weekly assessments included counts of blisters, crusts, and erosions, and assessments of alterations in cutaneous pain, healing times, and activity times before further blister formation. Although considerable variability in individual responses was noted, no significant difference was detectable between the active drug and its matched placebo. On the basis of these findings, it was concluded that 5% topical bufexamac is ineffective in the treatment of EB simplex.

(Arch Dermatol 1988;124:1669-1672)

×